# Augustine Therapeutics NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/augustine-therapeutics

- Industry: Biotechnology
- Headquarters: Leuven, Belgium
- Website: www.augustinetx.com
- Total disclosed funding: $53M
- Latest round: Series A (Feb 10, 2025)
- Investors on record: 12

## About

Augustine Therapeutics, based in Leuven, Belgium, focuses on developing innovative treatments through HDAC6 inhibitors for chronic neuromuscular and neurodegenerative conditions.Founded in 2019 in Leuven, Belgium, Augustine Therapeutics specializes in developing Histone Deacetylase 6 (HDAC6) inhibitors. The company operates with a strategic focus on advancing therapies for chronic conditions, and has engaged in three notable funding deals. The latest funding, a Series A round, raised EUR 77.7 million on March 24, 2025, featuring participation from various investors including Novo Holdings and Jeito Capital. The company was established by Joris de Wit, who has a history in the biotechnology sector, and currently led by CEO Sylvain Celanire.Augustine Therapeutics specializes in the development of novel Histone Deacetylase 6 (HDAC6) inhibitors, targeting chronic conditions such as neuromuscular and neurodegenerative disorders. Their lead product, AGT-100216, is the first selective HDAC6 inhibitor aimed specifically at Charcot-Marie-Tooth Disease (CMT), designed to selectively inhibit HDAC6 while maintaining its beneficial functions. The company is advancing a comprehensive pipeline of HDAC6 inhibitors focusing on neurologic and cardiometabolic diseases, primarily serving healthcare providers and research institutions in North America and Europe.Augustine Therapeutics' revenue strategy relies on partnerships and collaborations for the development and commercialization of its HDAC6 inhibitors. Revenue generation is structured around partnership agreements with pharmaceutical companies, encompassing milestone payments and potential royalties upon product commercialization. Their lead product AGT-100216 may utilize tiered or value-based pricing models in alignment with healthcare systems, thus ensuring accessibility while reflecting the therapeutic value offered.In March 2025, Augustine Therapeutics raised EUR 77.7 million in Series A funding to advance its lead candidate, AGT-100216. The company plans to further develop this product while exploring market expansion into North America and Europe, aiming for greater geographical reach by leveraging new partnerships. The recent funding will significantly support these initiatives, enhancing their capacity to deliver innovative solutions for chronic diseases.

## Funding rounds

- Series A, Feb 10, 2025, $38M — K.U. Leuven Research & Development, Novo Holdings, PMV, VIB, Eli Lilly & Company, V-Bio Ventures, AdBio Partners, Newton Biocapital Partners, Asabys Partners, Jeito Capital, CMT Research Foundation
- Series A, Jun 27, 2024, $12M — PMV, VIB, Eli Lilly & Company, V-Bio Ventures, AdBio Partners, Asabys Partners, CMTA
- Seed, Dec 6, 2019, $2.7M — K.U. Leuven Research & Development, PMV, VIB, V-Bio Ventures, AdBio Partners

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed, Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Seed, Series A
- VIB — Seed, Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Seed, Series A
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed, Series A
- Eli Lilly & Company — Series A
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series A
- CMTA — Series A
- Novo Holdings — Series A
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A
- CMT Research Foundation — Series A